

13 March 2025

The Manager
ASX Market Announcements
Australian Securities Exchange
Exchange Centre
Level 4
20 Bridge Street
Sydney NSW 2000

Australian Foundation
Investment Company Limited
ABN 56 004 147 120
Level 21, 101 Collins St
Melbourne VIC 3000
T 03 9650 9911
F 03 9650 9100
invest@afi.com.au
afi.com.au

Electronic Lodgement

**Australian Foundation Investment Company Limited
Information Meetings – Presentation**

Dear Sir / Madam

Please find attached the presentation to be given at the Information Meetings being held in March and April 2025.

Yours faithfully



Andrew Porter
Company Secretary

ASX Release authorised by the Company Secretary.

For personal use only

ersonal use only



Shareholder Meetings March/April 2025



ASX: AFI



ASX: DJW



ASX: MIR



ASX: AMH

Disclaimer

Australian Foundation Investment Company, Djerriwarrh Investments Limited, Mirrabooka Investments Limited and AMCIL Limited and their service provider Australian Investment Company Services Limited (AICS) (AFSL 303209), their related entities and each of their respective directors, officers and agents (together the Disclosers) have prepared the information contained in these materials in good faith. However, no warranty (express or implied) is made as to the accuracy, completeness or reliability of any statements, estimates or opinions or other information contained in these materials (any of which may change without notice) and to the maximum extent permitted by law, the Disclosers disclaim all liability and responsibility (including, without limitation, any liability arising from fault or negligence on the part of any or all of the Disclosers) for any direct or indirect loss or damage which may be suffered by any recipient through relying on anything contained in or omitted from these materials.

This information has been prepared and provided by AICS. To the extent that it includes any financial product advice, the advice is of a general nature only and does not take into account any individual's objectives, financial situation or particular needs. Before making an investment decision an individual should assess whether it meets their own needs and consult a financial advisor.

Agenda

- Overview – Mark Freeman
- Portfolios:
 - David Grace - AFIC
 - Olga Kosciuczyk - Djerriwarrh
 - Kieran Kennedy - Mirrabooka
 - Mark Freeman - AMCIL
- Closing Remarks – Mark Freeman
- Questions

Diversified Australian and New Zealand Equities – capital and fully franked dividend growth over the long term

MER | **0.15%**

Grossed up dividend yield

5.3%

\$10.2 billion

Fully franked yield that is higher than that available from the ASX 200 Index utilising option strategies, long term capital growth

MER | **0.42%**

Grossed up dividend yield

7.3%

\$880 million

Australian and New Zealand small/midcap sector, capital growth over the long term and fully franked dividends

MER | **0.56%**

Grossed up dividend yield

6.0%

\$660 million

High conviction portfolio, strong capital growth over the long term and fully franked dividends

MER | **0.56%**

Grossed up dividend yield

5.3%

\$400 million



Managing four funds with different investment objectives adds significantly to the effectiveness of the investment process and idea generation

Investment team with over 200 years experience

Total FUM of approximately \$12 billion

Dividend yields based on share price on 12 March 2025. Includes special dividends for Mirrabooka and AMCIL

We operate what is called The Traditional LIC Model

Internally managed – no external funds management business charging separate portfolio fees

Long term investor in diversified portfolios of quality companies - tax aware with lower portfolio turnover and with lower volatility of returns

Costs and tax paid have less of an impact on returns – our performance quoted after fees and tax paid


Incentives strongly aligned with shareholder interests, benefit of scale flows to shareholders

Sensitivity to income requirements of shareholders – profit reserves, focus on fully franked dividends

Independent Board of Directors

AFIC Portfolio* and Sector Performance to 28 February 2025

Personal use only




* Per annum returns. Assumes the full benefit of franking credits.

Past performance is not indicative of future performance.

Shareholder Meeting March/April 2025

12 Month Sector Performance




Includes dividends but not franking.

Portfolio Set to Perform in Most Economic Settings

Growth Companies



Cyclicals



Stalwarts



Income





Shareholder Meeting March/April 2025

Portfolio at 28 February 2025, excludes cash.

AUSTRALIAN
FOUNDATION
INVESTMENT
COMPANY

Banking Sector - Valuations




Source FactSet

Shareholder Meeting March/April 2025

ResMed – the benefit of long-term investing

ResMed - EPS vs Share Price



Note: ASX 200 is indexed to company's share price

Source: Diogenes Research


Shareholder Meeting March/April 2025




Source: ResMed

Djerriwarrh: Enhanced Yield and Capital Growth - 28 February 2025*

Enhanced Dividend Yield



Portfolio Per Annum Returns



*Assumes an investor can take full advantage of the franking credits. Yield based on the interim dividend and final dividend paid – in total 15 cents per share.


Past performance is not indicative of future performance.

Shareholder Meeting March/April 2025

Portfolio Update: Recent Purchases




Dividend per Share



Shareholder Meeting March/April 2025



Cochlear®
Sales revenue
\$ million



Portfolio Update: Summary

Constructing a diversified portfolio of **high-quality** companies across different sectors and with the appropriate balance of **Income and Growth** is the key for Djerriwarrh to deliver on its Investment Objectives in a variety of market conditions.

Key Portfolio Statistics

\$850m	45
Portfolio Value*	Stocks in the Portfolio
39%	1%
Call Option Exposure	Put Option Exposure
\$3.29	
Net Tangible Asset (NTA) Backing Per Share	


Source: Based on 28 February 2025 Portfolio.

* Portfolio Value is based on the Investment Portfolio plus the Trading portfolio, not including the Options portfolio and cash.

Top 20 Holdings



Mirrabooka Portfolio Performance – Per Annum Returns to 28 February 2025*



- Net asset per share growth plus dividends, including franking
- S&P/ASX Mid Cap 50 and Small Ordinaries Accumulation Indices, including franking

* Assumes an investor can take full advantage of the franking credits. Mirrabooka's portfolio return is also calculate after management fees, income tax and capital gains tax on realised sales of investments. It should be noted that Index returns for the market do not include management expenses or tax.

Past performance is not indicative of future performance.

ersonal use only

Investment Portfolio activity* – selected material transactions

Investment Portfolio purchases – total \$46 million

New to the portfolio

Cuscal 



Addition to existing holding



EVT

Cobram Estate


Investment Portfolio sales – total \$77 million

Exiting the portfolio



 **PSC INSURANCE GROUP**


Reduction in ongoing holding

Fisher & Paykel HEALTHCARE

netwealth











 **gentrack™**











 **REA Group**

 **Pinnacle**

*Six months to 31 December 2024

Mirrabooka Top 20 Holdings – 28 February 2025


	Company	% of Portfolio	Ownership Period
1	 macquarie TECHNOLOGY GROUP	4.6%	8 yrs
2	 TEMPLE & WEBSTER	4.3%	5 yrs
3	 ARB	4.1%	14.5 yrs
4	 gentrack™	3.3%	3 yrs
5*	 ResMed	3.3%	13.5 yrs
6	 ALS	3.1%	19.5 yrs
7	 MANREIGH	3.1%	9.5 yrs
8	 EVT	2.8%	14.5 yrs
9	 Equity Trustees	2.7%	19.5 yrs
10*	 CAR Group	2.6%	8.5 yrs

	Company	% of Portfolio	Ownership Period
11	 Breville™	2.6%	7.5 yrs
12*	 HUB ²⁴	2.3%	9.5 yrs
13	 VISTA GROUP	2.2%	2.5 years
14	 idp	2.1%	4 yrs
15*	 netwealth	2.0%	7.5 yrs
16	 Region	2.0%	1.5 years
17	 Cobram Estate	1.8%	2 yrs
18	 Worley energy chemicals resources	1.7%	3 yrs
19	 JamesHardie™	1.7%	6.5 yrs
20	 Objective	1.7%	10.0 yrs

* Indicates that options were outstanding against part of the holding.

Note: ResMed, Breville Group, Vista Group, IDP Education, Worley and James Hardie have been held previously by Mirrabooka.


AMCIL Portfolio Performance – Per Annum Returns to 28 February 2025*



* Assumes an investor can take full advantage of the franking credits. AMCIL's portfolio return is also calculated after management fees, income tax and capital gains tax on realised sales of investments. It should be noted that Index returns for the market do not include management expenses or tax.





















Past performance is not indicative of future performance.

Recent Selected Portfolio Activity*



*Six months to 31 December 2024

AMCIL Top 20 Holdings – 28 February 2025

	Company	% of Portfolio	Ownership Period		Company	% of Portfolio	Ownership Period
1	 CSL™	8.1%	13 yrs	11	 ResMed	3.2%	5.5 yrs
2	 MACQUARIE BANK	6.0%	7 yrs	12	 netwealth	2.8%	3.5 yrs
3*	 Wesfarmers	4.6%	6 yrs	13	 JamesHardie™	2.7%	13 yrs
4	 BHP	4.5%	21 yrs	14	 Equity Trustees	2.3%	7.5 yrs
5	 Goodman	4.4%	5.5 yrs	15	 ALS	2.3%	2.5 yrs
6*	 Transurban	4.1%	15 yrs	16	 wisetech global	2.3%	2 yrs
7	 LINFOIL	4.0%	9.5 yrs	17	 amcor	2.2%	0.5 yrs
8	 CAR Group	3.9%	7.5 yrs	18	 REA Group®	2.2%	5 yrs
9	 macquarie TECHNOLOGY GROUP	3.5%	5.5 yrs	19	 gentrack™	1.9%	2 yrs
10	 ARB	3.4%	14.5 yrs	20	 Fisher & Paykel HEALTHCARE	1.8%	4 yrs

* Indicates options were outstanding against some of the holding .

Note: Wesfarmers, Transurban, Macquarie Technology Group, ResMed, Netwealth, James Hardie, EQT, ALS, Amcor, REA and Fisher and Paykel have been held previously by AMCIL.

Shareholder Meeting March/April 2025




Key Themes from the Recent Company Reporting Season

- Majority of the companies reported results in line with expectations.
- Outlook statement and earnings guidance however were on average below market expectations
- Cost efficiencies helping to support margins.
- Australian consumers remain in reasonable health.
- Balance sheets generally in good shape.
- More mentions of using AI in businesses.


Where the market is currently trading against the long term

ASX 200 Index Price Earnings Ratio



Source: FactSet


ASX 200 Index Dividend Yield



Personal use only

Where the US market is currently trading against the long term

S&P500 Index Price Earnings Ratio



Source: FactSet

S&P500 Index Dividend Yield



The case for our LICs over Index ETF's

Closed end fund provides stability of capital which allows for long term investment

Investments strategies are not influenced by the issuance and redemption of units as they are in open ended structures – better able to take advantage of market opportunities





LICs not wedded to tracking an index that may lead to:

- forced buying in overheated markets – last buyer of upgrades
- forced selling value in falling markets – last seller of downgrades
- large exposure to an individual company/sector

Greater stability of fully franked dividends, simple distributions, benefit of LIC capital gains. No unexpected tax outcome for investors

As an active investment manager, we have the discretion to take advantage of discounted placements, buy backs and other corporate actions on behalf of shareholders

Share price relative to Net Asset Backing – 28 February 2025



ersonal use only

